Fingerprint
Dive into the research topics of 'Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
BFORE study investigators
Research output: Contribution to journal › Article › peer-review
47
Scopus
citations